The present Section 3 research of larazotide ought to present ends in This fall of 2021, says Blair, and, if optimistic, the corporate will file for conditional approval within the U.S. Even failure to obtain conditional approval should not be an excessive amount of of a near-term danger for the inventory. The important thing would be the optimistic Section 3 consequence.
Blair says comparable corporations commerce at a market cap of $1.9B vs. 9 Meters’ $95M.
Shares are up 10% premarket.
Extra on larazotide right here: 9 Meters Bio nabs new patent for larazotide in U.S. (July 28)